Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

141. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer

Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – European Society of Gastrointestinal Endoscopy (ESGE) +49-89-9077936-11 Menu DOI https://doi.org/10.1055/a-1016-4977 | Endoscopy 2019; 51:1082–1093 Published online: 9.10.2019 © Georg Thieme Verlag KG Stuttgart · New York Explore the ESGE website Menu Contact us +49

2019 European Society of Gastrointestinal Endoscopy

142. Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer

Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline – European Society of Gastrointestinal Endoscopy (ESGE) +49-89-9077936-11 Menu DOI https://doi.org/10.1055/a-0831-2522 Endoscopy 2019; 51: 266–277 © Georg Thieme Verlag KG Stuttgart· New York Explore the ESGE

2019 European Society of Gastrointestinal Endoscopy

143. Pertuzumab (Perjeta) after surgery for some breast cancers at high risk of recurrence

Pertuzumab (Perjeta) after surgery for some breast cancers at high risk of recurrence Prescrire IN ENGLISH - Spotlight ''Sample Free Download article (titre court pour FB et Twitter)'', 1 December 2019 {1} {1} {1} | | > > > Sample Free Download article (titre court pour FB et Twitter) Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the December (...) issue of Prescrire International: pertuzumab (Perjeta°) after surgery for some breast cancers at high risk of recurrence FREE DOWNLOAD Pertuzumab (Perjeta°) is a monoclonal antibody which has been authorised for use after surgery for some breast cancers. How do Prescrire's editors rate the drug's harm-benefit balance in this situation, in light of the most recent evidence? Full text available for free download. Summary Pertuzumab (Perjeta°, Roche) is a monoclonal antibody with anti-HER2 activity

2019 Prescrire

144. Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy?

Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy? 1 Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care (...) research. www.acfp.ca November 25, 2019 (en français) Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy? Clinical Question: Does hydrochlorothiazide increase the risk of squamous cell carcinoma (SCC) of the skin? Bottom Line: Observational data suggest an association between hydrochlorothiazide and the risk of SCC. Causation has not been proven. Risk appears to consistently increase with dose and duration (example: 5 years of use increases risk 3-4 times). Baseline

2019 Tools for Practice

145. Atezolizumab (Tecentriq) - metastatic non-squamous non-small cell lung cancer (NSCLC)

Atezolizumab (Tecentriq) - metastatic non-squamous non-small cell lung cancer (NSCLC) Published 09 December 2019 1 Statement of advice SMC2254 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) Roche Products Ltd 8 November 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation atezolizumab (Tecentriq®) is not recommended for use within NHSScotland. Indication under review: In combination with nab-paclitaxel and carboplatin for the first (...) -line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium

2019 Scottish Medicines Consortium

146. Olaparib (Lynparza) - advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer

Olaparib (Lynparza) - advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer Published 09 December 2019 1 SMC2209 olaparib 100mg and 150mg film-coated tablets (Lynparza®) AstraZeneca UK Limited. 8 November 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland (...) . The advice is summarised as follows: ADVICE: following a full submission considered under the orphan equivalent process olaparib (Lynparza ® ) is accepted for use within NHSScotland. Indication under review: for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based

2019 Scottish Medicines Consortium

147. Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines

Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines - Crow - 2019 - Transplant International - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term Original (...) Article Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines Department of Dermatology, University of California San Francisco, San Francisco, CA, USA Division of Dermatology, Dell Medical School, University of Texas at Austin, Austin, TX, USA Montgomery Dermatology/Lankenau Institute for Medical Research, King of Prussia, PA, USA Advanced Heart Failure Center, Sentara Heart Hospital, Norfolk, VA, USA

2019 International Society for Heart and Lung Transplantation

148. Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Apalutamide (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 April 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-09 Apalutamide (...) (prostate cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-09 Version 1.0 Apalutamide (prostate cancer)) 24 April 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Apalutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 24 January 2019 Internal

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

149. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Full Text available with Trip Pro

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Colorectal cancer... Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline (Published 02 October 2019) Cite (...) this as: BMJ 2019;367:l5515 Visual summary of recommendation No screening FIT Every year FIT Every two years Sigmoidoscopy Single Colonoscopy Single Favours no screening Favours screening We suggest no screening Interventions compared Recommendations Screening options Population We suggest using a tool such as the QCancer® calculator to estimate the risk of colorectal cancer for each person in the next 15 years. This calculates risk, based on: Understanding a person’s risk of cancer can help to determine

2019 BMJ Rapid Recommendations

150. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab T echnology appraisal guidance Published: 20 November 2019 www.nice.org.uk/guidance/ta612 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612) © NICE 2019. All rights

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

151. Irreversible electroporation for primary liver cancer

Irreversible electroporation for primary liver cancer Irreversible electroporation for primary liver cancer Interventional procedures guidance Published: 27 November 2019 www.nice.org.uk/guidance/ipg664 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does (...) Recommendations 1.1 Evidence on the safety of irreversible electroporation for primary liver cancer shows serious but infrequent and well-recognised complications. Evidence on its efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research. 1.2 Patient selection should be done by a multidisciplinary team. 1.3 The procedure should only be done in specialist centres by clinicians with experience and specific training. 1.4 Further research could

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

152. Niraparib (Zejula) - epithelial ovarian, fallopian tube, or primary peritoneal cancer

Niraparib (Zejula) - epithelial ovarian, fallopian tube, or primary peritoneal cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written

2019 Health Canada - Drug and Health Product Register

153. Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma

Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

154. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer SPECIAL ARTICLE EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees † A. Horwich 1 * , M. Babjuk 2,3 , J. Bellmunt 4,5 , H. M. Bruins 6 , T. M. De Reijke 7 , M. De Santis 3,8 , S. Gillessen 9,10,11,12 , N. James 13,14 , S. Maclennan 15 , J. Palou 16 , T (...) , R. Zigeuner 133 & J. A. Witjes 6 1 Emeritus Professor, The Institute of Cancer Research, London, UK; 2 Depatment of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic; 3 Department of Urology, Medical University of Vienna, Vienna, Austria; 4 IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; 5 Harvard Medical School, Boston, USA; 6 Department of Urology, Radboud University Medical Center, Nijmegen; 7 Department of Urology, Amsterdam

2019 European Society for Medical Oncology

155. Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V

Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Rucaparib (Ovarialkarzinom; Erhaltungstherapie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.1; Status: 7 August 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A19-23 Rucaparib (ovarian cancer; maintenance treatment) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-23 Version 1.1 Rucaparib (ovarian cancer; maintenance treatment) 7 August 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Rucaparib (ovarian cancer; maintenance treatment) – Benefit assessment

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

156. Ribociclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A19-06

Ribociclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A19-06 1 Translation of addendum A19-46 Ribociclib (Mammakarzinom; Kombination mit einem Aromatasehemmer) – Addendum zum Auftrag A19-06 (Version 1.0; Status: 14 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 14 June 2019 1.0 Commission: A19-46 (...) Version: Status: IQWiG Reports – Commission No. A19-46 Ribociclib (breast cancer; combination with an aromatase inhibitor) – Addendum to Commission A19-06 1 Addendum A19-46 Version 1.0 Ribociclib – Addendum to Commission A19-06 14 June 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ribociclib (breast cancer; combination with an aromatase inhibitor) – Addendum to Commission A19-06

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

157. Ribociclib (breast cancer; combination with fulvestrant) - Addendum to Commission A19-06

Ribociclib (breast cancer; combination with fulvestrant) - Addendum to Commission A19-06 1 Translation of addendum A19-45 Ribociclib (Mammakarzinom; Kombination mit Fulvestrant) – Addendum zum Auftrag A19-06 (Version 1.0; Status: 17 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 17 June 2019 1.0 Commission: A19-45 Version: Status: IQWiG (...) Reports – Commission No. A19-45 Ribociclib (breast cancer; combination with fulvestrant) – Addendum to Commission A19-06 1 Addendum A19-45 Version 1.0 Ribociclib – Addendum to Commission A19-06 17 June 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ribociclib (breast cancer; combination with fulvestrant) – Addendum to Commission A19-06 Commissioning agency: Federal Joint Committee

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

158. Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Dacomitinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A19-39 Dacomitinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-39 Version 1.0 Dacomitinib (non-small cell lung cancer) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dacomitinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

159. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study (Abstract)

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study In the phase 3 TITAN study, the addition of apalutamide to androgen deprivation therapy (ADT) significantly improved the primary endpoints of overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer. We aimed to assess health-related quality of life (...) (HRQOL) in TITAN, including pain and fatigue.In this randomised, placebo-controlled, double-blind, phase 3 study, patients with metastatic castration-sensitive prostate cancer (defined as not receiving ADT at the time of metastatic disease progression) aged 18 years and older, receiving continuous ADT (selected at the investigator's discretion), and with an Eastern Cooperative Oncology Group performance status score of 0 or 1 were randomly assigned (1:1), using an interactive web response system

2019 EvidenceUpdates

160. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis

Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis Indirect Comparisons of Efficacy Between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Review Eur Urol Actions 2019 Oct 31 [Online ahead of print] Indirect Comparisons of Efficacy Between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis

2019 EvidenceUpdates